Quantum Cyber N.V. Unveils Investor Presentation Showcasing Autonomous Defense Platform and US Manufacturing Footprint
QUCY has more than doubled off its 52-week low of $0.3.
Summary
Quantum Cyber N.V. released an investor presentation outlining its autonomous defense platform, IP portfolio, and newly acquired US manufacturing facility, providing the most detailed public disclosure since its pivot from life sciences.
Key Events · Corporate Governance and Compliance · QUCY
-
Investor Presentation Filed
The company furnished an investor presentation as Exhibit 99.1 to an 8-K, detailing its autonomous defense platform, IP portfolio, and manufacturing facility.
-
Tri-Domain Autonomous Platform
The presentation outlines a single AI brain (QC-Core) powering air, ground, and maritime systems, with flagship platforms SWARM-X ($500/unit) and FALCON 55 ($70,000/unit) under LOI with General Cherry and SOCOM.
-
IP Portfolio and Quantum License
Eight filed patent positions (6 provisional, 1 pending, 1 USPTO-filed) plus an exclusive worldwide license to Project LightShift's quantum photonic array technology, signed June 11, 2026.
-
US Manufacturing Facility Acquired
Quantum Drones Corp closed the acquisition of a ~50,000 sq ft industrial facility in Bridgeport, CT, on July 15, 2026, for $2.3M, with ~$2.09M in assumed open purchase orders and a targeted annual capacity of 100,000 drones.
Analysis · QUCY · Life Sciences
Quantum Cyber N.V. has furnished an investor presentation that offers the most comprehensive public view yet of its pivot to autonomous defense. The deck details a tri-domain AI platform, eight filed patent positions, an exclusive quantum-antenna license, and the July 2026 acquisition of a 50,000 sq ft manufacturing facility in Bridgeport, CT. It also discloses signed letters of intent with General Cherry and SOCOM, a clean capital structure with 27.64M basic shares and no debt, and a targeted annual production capacity of 100,000 drones. For a company that recently completed a radical business pivot and a $250M shelf registration, this presentation is a key piece of the narrative — it puts hard assets and a procurement pipeline behind the story, which could influence investor perception and future capital-raising efforts.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QUCY was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $0.30 to $4.93. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.